Lineage cell Therapeutics discussed the COR1 cell transplant project and the membrane mesotheliosis manufacturing strategy

Lineage cell Therapeutics, Inc. (LCTX) discussed the COR1 cell transplant project and its manufacturing strategy for membrane membranes. Corporate executives include Ioana Hone, Director General of Investor Relations, Brian Culley, CEO, and Priyantha Herath, Senior Vice President of Clinical Operations. It was mentioned that the actual performance of companies might differ significantly from expectations and that investors should be cautious about forward-looking statements。